Results 1 to 10 of about 79,191 (189)
Maritoclax Overcomes FBW7 Deficiency‐Driven Irinotecan Resistance in Colorectal Cancer by Targeting MCL1 [PDF]
Cancer MedicineIntroduction FBW7, a tumor suppressive E3 ubiquitin ligase frequently mutated in colorectal cancer (CRC), mediates chemotherapy resistance. While irinotecan (via its active metabolite SN38) is a first‐line TOP1 inhibitor for advanced CRC, the mechanistic
Qian Lin +4 more
doaj +2 more sources
Acta Pharmaceutica Sinica B, 2023 Irinotecan is an anticancer topoisomerase I inhibitor that acts as a prodrug of the active metabolite, SN-38. Unfortunately, the limited utility of irinotecan is attributed to its pH-dependent stability, short half-life and dose-limiting toxicity.
Shiwen Song +9 more
doaj +1 more source
Hepatic ROS Mediated Macrophage Activation Is Responsible for Irinotecan Induced Liver Injury
Cells, 2022 Irinotecan is the first line chemotherapy drug used for treatment of metastatic colorectal cancer worldwide. There is increasing evidence suggesting that liver damage, including steatosis and steatohepatitis, can be caused during the treatment involving ...
Bohao Liu +7 more
doaj +1 more source
Scientific Reports, 2023 Irinotecan is a topoisomerase I inhibitor which has been widely used to combat several solid tumors, whereas irinotecan therapy can induce liver injury.
Congjian Shi +4 more
doaj +1 more source
Irinotecan-Induced Dysarthria [PDF]
Case Reports in Oncology, 2012 Colorectal carcinomas are among the most common tumor types and are generally treated with palliative chemotherapy in case of metastatic disease. Here, we describe the case of a 46-year-old patient with metastatic rectal carcinoma who received second-line therapy with irinotecan and developed isolated transient dysarthria (with normal MR imaging of the
Dressel, A.J. +4 more
openaire +4 more sources
Identification of Sestrin3 Involved in the In vitro Resistance of Colorectal Cancer Cells to Irinotecan. [PDF]
PLoS ONE, 2015 Irinotecan, an analogue of camptothecin, is frequently used as a single agent or in combination with other anticancer drugs for the treatment of colorectal cancer. However, the drug resistance of tumors is a major obstacle to successful cancer treatment.
Seung Ho Choi +4 more
doaj +1 more source
CPT: Pharmacometrics & Systems Pharmacology, 2021 Liposomal irinotecan is a liposomal formulation of irinotecan, which prolongs circulation of irinotecan and its active metabolite SN‐38. A population pharmacokinetic (PK) model was developed based on data from seven studies (N = 440).
Karl Brendel +10 more
doaj +1 more source
Case Reports in Oncology, 2021 Irinotecan hydrochloride (irinotecan) is a chemotherapeutic agent used in the treatment of solid tumors. In addition to severe neutropenia and delayed diarrhea, irinotecan causes cholinergic syndrome, characterized by abdominal pain and acute diarrhea ...
Kazuki Uchiyama +4 more
doaj +1 more source
Establishment and Characterization of an Irinotecan-Resistant Human Colon Cancer Cell Line
Frontiers in Oncology, 2021 Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide. Irinotecan is widely used as a chemotherapeutic drug to treat CRC. However, the mechanisms of acquired resistance to irinotecan in CRC remain inconclusive.
Zhuo-Xun Wu +7 more
doaj +1 more source
Therapeutic Advances in Medical Oncology, 2021 Introduction: Liposomal irinotecan (nal-IRI) plus fluorouracil/leucovorin (5-FU/LV) has shown clinical benefit in patients with metastatic pancreatic adenocarcinoma (mPAC) who progressed on gemcitabine-based chemotherapy.
Kyunghye Bang +6 more
doaj +1 more source